VIELA BIO

A clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease

Learn More

Our Portfolio

Viela Bio is building a portfolio of innovative biologics that either are first in class or have the potential to be best in class

Our Team

Viela Bio is led by a team of motivated industry experts, aiming to make a difference for inflammation and autoimmunity patients

Our Recent News

Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting

| Company General News | No Comments
Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting Company to hold…

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

| Company General News | No Comments
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18,…

Viela Bio Announces Pivotal Study Results of Inebilizumab in NMOSD to be Presented in a Plenary Session at the 2019 American Academy of Neurology Annual Meeting

| Company General News | No Comments
Viela Bio Announces Pivotal Study Results of Inebilizumab in NMOSD to be Presented in a Plenary Session at the 2019 American Academy of Neurology Annual Meeting Gaithersburg, MD—March 7, 2019…

Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

| Company General News | No Comments
Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Gaithersburg, MD—January 3, 2019 –Viela Bio today announced that…